Search

Pathophysiology of diabetic macular oedema: why combination therapy may be better

The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...

Myasthenia gravis presenting with isolated ptosis: a poorly studied subgroup

Investigation into the cause of one isolated symptom or sign can be challenging if that particular sign may be caused by a variety of pathological processes, affecting different tissues, and presenting to different specialties. Unilateral ptosis is a case in...

Learnings and trends in the management of open-angle and angle-closure glaucoma

To be truly disruptive, newer technologies need to offer a quality of life benefit over medication to a broad population of glaucoma sufferers. Evidence and converging trends in medical and surgical management of glaucoma were explored in counterpoint discussions and...

See sweet to C-suite: Imran Rahman

See also - See sweet to C-suite: Peter Holland In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part Two: David speaks...

#KnowYourDrops: breaking down barriers to poor compliance

Award-winning* #KnowYourDrops eye drop compliance campaign helps patients for World Glaucoma Week to achieve medicines optimisation in ophthalmology. The #KnowYourDrops campaign is fast becoming an internationally recognised model to help support healthcare professionals, with the provision of better tailored ophthalmic...

Innovations in ophthalmology: what can the innovations of the past teach us about tomorrow?

BUOS Prize Essay – 2nd prize winner for 2013 submissions Introduction An essay titled Innovations in Ophthalmology might choose to focus on the history; from cataract couching to femtosecond lasers, ophthalmology has had no shortage of topics worthy of discussion....

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...

Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service

Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...